Skip to content

Application of Oliceridine Combined with Fascia Iliaca Compartment Block for Patient-Controlled Analgesia in Elderly Frail Patients after Total Hip Arthroplasty

Application of Oliceridine Combined with Fascia Iliaca Compartment Block for Patient-Controlled Analgesia in Elderly Frail Patients after Total Hip Arthroplasty

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112429
Enrollment
Unknown
Registered
2025-11-13
Start date
2025-05-22
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Analgesia

Interventions

Group A(Oliceridine Group):Preparation of postoperative analgesia intravenous pump using Oliceridine at 0.3 mg/kg
Group S(Sufentanil Group):Preparation of postoperative analgesia intravenous pump using Sufentanil at 0.15ug/kg

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Aged 65–95 years, heart rate 60–100 beats per minute, BMI 18.5–23.9 kg/m²; 2. American Society of Anaesthesiologists (ASA) physical status classification II–III; 3. Patients scheduled for hip replacement surgery under spinal anaesthesia; 4. Generally good physical condition with no underlying medical conditions or well-controlled underlying conditions; 5. Frailty Scale score =3 points.

Exclusion criteria

Exclusion criteria: 1. Severe haematological, circulatory, or respiratory disorders, as well as substantial renal lesions; 2. Allergy to any administered medication; 3. Poorly controlled underlying medical conditions; 4. Long-term use of psychotropic drugs or severe consciousness impairment; 5. History of alcohol abuse, drug use, or substance misuse; 6. Non-cooperation from the patient or their family; 7. Contraindications to nerve block; 8. Contraindications to spinal anaesthesia.

Design outcomes

Primary

MeasureTime frame
Composite incidence of adverse reactions within 48 hours (including respiratory depression, anxiety, headache, dizziness, nausea, vomiting, constipation, and pruritus).;

Secondary

MeasureTime frame
sedation level;pain level;cognitive function;comprehensive analgesic effect evaluation;quality of recovery;

Countries

China

Contacts

Public ContactLiu Zhenguo

Weifang People's Hospital

Lzg1002@163.com+86 135 6369 9799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026